Last 98.45 INR
Change Today 0.00 / 0.00%
Volume 0.0
As of 7:06 AM 08/28/14 All times are local (Market data is delayed by at least 15 minutes).

rpg life sciences ltd (RPGL) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/3/14 - 122.05
52 Week Low
02/7/14 - 44.60
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for RPG LIFE SCIENCES LTD (RPGL)

Related News

No related news articles were found.

rpg life sciences ltd (RPGL) Related Businessweek News

No Related Businessweek News Found

rpg life sciences ltd (RPGL) Details

RPG Life Sciences Limited, an integrated pharmaceutical company, develops, manufactures, and markets branded formulations, generic dosage forms, and synthetic and fermentation active pharmaceutical ingredients (APIs) in India and internationally. The company offers synthetic APIs in various therapeutic categories, including immunosuppressants, anti-psychotic/anti-depressant, anti-thrombotic, anti-anginal, anti-helmentic, anti-convulsant, anti-spasmodic, and anti-cancer. It also provides generics primarily in the area of immunosuppressant therapy; finished dosage formulations for various therapies, such as gastro-intestinal, pain management, cardio-vascular, and nephrology primarily under the Lomotil, Lomofen, Naprosyn, Azoran, Aldactone, and Serenace brand names; and biotechnology products in the areas of oncology. RPG Life Sciences Limited offers its products in various dosage forms, including tablets, capsules, and syrups. The company was formerly known as RPG Pharmaceuticals Limited and changed its name to RPG Life Sciences Limited in February 2008. RPG Life Sciences Limited was founded in 1968 and is based in Mumbai, India.

Founded in 1968

rpg life sciences ltd (RPGL) Top Compensated Officers

Managing Director, Director, Member of Audit ...
Total Annual Compensation: 15.3M
Compensation as of Fiscal Year 2013.

rpg life sciences ltd (RPGL) Key Developments

RPG Life Sciences Limited Appoints Narendra Ambwani as an Additional Director

RPG Life Sciences Limited has informed that the Board of Directors of the Company at its meeting held on July 24, 2014, has appointed Mr. Narendra Ambwani as an Additional Director on the Board of the Company with immediate effect. He qualifies to be an Independent Director as defined in Clause 49 of the Listing Agreement and Section 149 of the Companies Act, 2013.

RPG Life Science Limited Announces Unaudited Standalone Earnings Results For the Three Months Ended June 30, 2014

RPG Life Science limited announced unaudited standalone earnings results for the first quarter ended June 30, 2014. For the quarter, the company reported net sales/income from operation (net of excise duty) of INR 587.9 million compared with INR 629.0 million for the same period in the last year. Net profit for the period was INR 11.6 million compared with INR 546.9 million for the same period in the last year. Basic and diluted earnings per share were INR 0.70 compared with INR 33.07 for the same period in the last year. profit from operations before other income, finance costs and exceptional items was INR 12.0 million compared with INR 58.8 million for the same period in the last year. Profit from ordinary activities before tax was INR 11.0 million compared with INR 693.7 million for the same period in the last year.

RPG Life Sciences Limited to Report Q1, 2015 Results on Jul 24, 2014

RPG Life Sciences Limited announced that they will report Q1, 2015 results on Jul 24, 2014


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RPGL:IN 98.45 INR 0.00

RPGL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RPGL.
View Industry Companies

Industry Analysis


Industry Average

Valuation RPGL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.7x
Price/Book 1.3x
Price/Cash Flow 15.9x
TEV/Sales 0.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RPG LIFE SCIENCES LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at